Rocklatan header logo
MENU CLOSE

About Rocklatan®

Once-daily Rocklatan® is the first and only elevated eye pressure drop that combines two powerful medications, Rhopressa® (netarsudil ophthalmic solution) 0.02% and latanoprost, into one eye drop with superior IOP reduction to individual components, latanoprost and Rhopressa® alone—which may help to slow the progression of glaucoma.

In clinical studies, Rocklatan® outperformed latanoprost by providing significantly better eye pressure reduction.

Rocklatan® combines the groundbreaking science behind Rhopressa® with the long-standing effectiveness of latanoprost.

Rocklatan® is a simple, single-bottle, once-daily eye drop that can fit any schedule.

Proven superior to latanoprost alone at lowering elevated eye pressure

In 2 clinical trials, Rocklatan® was studied in over 900 patients and was proven to reduce eye pressure significantly better than latanoprost alone—all with the ease of a single, once-daily dose.

58% of patients taking Rocklatan® achieved a target IOP of 16 mmHg or less


Talk to your doctor about your treatment options

Here’s a guide to help jump start your conversation.


Safety and possible side effects

The most frequent side effect reported in clinical studies was red eye. Other reported side effects included mild pain upon instillation, small deposits on the outer surface of the eye, and broken blood vessels on the white of the eye. These side effects were non-sight-threatening.

For more information, refer to the full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you wish to report a suspected issue with our product quality or possible adverse event involving one of our products, please contact Aerie Pharmaceuticals at 1-855-740-1924.

Remember: Please consult with your doctor before stopping medication.


Start saving on Rocklatan® and pay as little as $25* with eligible commercial insurance.

Restrictions apply. Patients with State or Federal coverage, such as Medicare or Medicaid, are excluded. 
See terms and conditions.

Patient instructions: In order to redeem this offer you must have a valid prescription for Rocklatan® or Rhopressa®. This offer may not be redeemed for cash. By using this offer, you are certifying that you meet the eligibility criteria and will comply with the terms and conditions described in the Restrictions section below. Patients who are enrolled in a state or federally funded prescription insurance program, such as Medicare or Medicaid, are excluded. Patients with questions about the Rocklatan® or Rhopressa® Savings offer should call 1-844-807-9706.

Eligible commercially insured patients with coverage for Rocklatan® or Rhopressa® will pay the first $25 per 30-day supply, maximum savings limit applies; patient out-of-pocket expense may vary. Offer valid up to 12 qualifying prescriptions.

Eligible commercially insured patients who are not covered for Rocklatan® or Rhopressa® will pay the first $50 per 30-day supply, maximum savings limit applies; patient out-of-pocket expense may vary. Offer valid for up to 6 qualifying prescriptions.

Pharmacist instructions for patients with commercial insurance coverage for Rocklatan® or Rhopressa®: Submit the claim to the primary commercial insurance company first, then submit the balance due to CHANGE HEALTHCARE as a Secondary Payer COB with patient responsibility amount and a valid Other Coverage Code of 8. The patient is responsible for the first $25. Reimbursement will be received from CHANGE HEALTHCARE.

Pharmacist instructions for patients with commercial insurance that are not covered: Submit this claim to CHANGE HEALTHCARE. A valid Other Coverage Code of 3 is required. The patient is responsible for the first $50. Reimbursement will be received from CHANGE HEALTHCARE.

For any questions regarding CHANGE HEALTHCARE online processing, please call the Help Desk 1-800-433-4893.

Restrictions: This offer is valid for eligible residents of the United States only. This offer is void in U.S. territories including, but not limited to, Puerto Rico. Offer not valid for prescriptions reimbursed under Medicare, a Medicaid drug benefit plan, TRICARE, CHAMPUS or other federal or state health programs. Offer may not be combined with any savings, discount, trial or similar offer for the same prescription. No other purchase is necessary. Coupon is not insurance. By using this offer, the patient certifies that he or she will comply with any terms of his or her health insurance contract requiring notification to his or her payor of the existence and/or value of this offer. Offer not valid for patients under 18 years of age. It is illegal to (or offer to) sell, purchase, trade, or counterfeit this offer. This offer is not transferable. Void where prohibited by law. Absent a change in Massachusetts law, for Massachusetts residents only, this offer will expire on December 31, 2019. Program managed by ConnectiveRx on behalf of Aerie Pharmaceuticals. Aerie Pharmaceuticals reserves the right to rescind, revoke or amend this offer without notice at any time.

BY USING THIS CARD, YOU AND YOUR PHARMACIST UNDERSTAND AND AGREE TO COMPLY WITH THESE ELIGIBILITY REQUIREMENTS AND TERMS OF USE.

IMPORTANT SAFETY INFORMATION

Contraindications

None.

Warnings and Precautions

Rocklatan® contains latanoprost, which may cause darkening of the eye color, darkening of the eyelid and eyelashes, and increased growth and thickness of eyelashes. Color changes may increase as long as Rocklatan® is administered, and eye color changes are likely to be permanent. Eyelash changes are usually reversible upon discontinuation of treatment.

Rocklatan® should be used with caution and may cause inflammation inside the eye or make existing inflammation worse.

Rocklatan® may cause macular edema (swelling of the macula) and should be used with caution in patients without a natural lens, in patients with a torn posterior lens capsule who have an artificial lens implant, or in patients with known risk factors for macular edema.

Rocklatan® should be used with caution in patients with a history of herpetic keratitis and not used in patients with active herpes simplex keratitis.

Avoid allowing the tip of the bottle to touch the eye to avoid bacterial eye infection which has been reported with the use of multiple-dose containers of topical ophthalmic products.

Contact lenses should be removed prior to using Rocklatan®. Contact lenses can be reinserted 15 minutes following administration of Rocklatan®.

If you have eye surgery, eye trauma or infection, or develop any eye reactions, immediately consult with your physician about continuing treatment with Rocklatan®.

Adverse reactions

The most common side effect for Rocklatan® in controlled clinical studies were red eyes (59%). Five percent of patients discontinued therapy due to red eyes. Other common side effects were pain upon instillation of eye drop (20%), small deposits on the outer surface of the eye (corneal verticillata) (15%), and broken blood vessels (11%). Eye itching, visual acuity reduced, excessive tearing, eye discomfort upon administration of eye drop, and blurred vision were reported in 5-8% of patients.

Be sure to contact your doctor if you have any questions.

Please click here for full prescribing information for Rocklatan®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATIONS AND USAGE

Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is a prescription medication for the treatment of high eye pressure/intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of Rocklatan® should not exceed once daily. Rocklatan® may be used together with other eye drops to lower high eye pressure/IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

IMPORTANT SAFETY INFORMATION

Contraindications

None.

Warnings and Precautions

Rocklatan® contains latanoprost, which may cause darkening of the eye color, darkening of the eyelid and eyelashes, and increased growth and thickness of eyelashes. Color changes may increase as long as Rocklatan® is administered, and eye color changes are likely to be permanent. Eyelash changes are usually reversible upon discontinuation of treatment.

Rocklatan® should be used with caution and may cause inflammation inside the eye or make existing inflammation worse.

Rocklatan® may cause macular edema (swelling of the macula) and should be used with caution in patients without a natural lens, in patients with a torn posterior lens capsule who have an artificial lens implant, or in patients with known risk factors for macular edema.

Rocklatan® should be used with caution in patients with a history of herpetic keratitis and not used in patients with active herpes simplex keratitis.

Avoid allowing the tip of the bottle to touch the eye to avoid bacterial eye infection which has been reported with the use of multiple-dose containers of topical ophthalmic products.

Contact lenses should be removed prior to using Rocklatan®. Contact lenses can be reinserted 15 minutes following administration of Rocklatan®.

If you have eye surgery, eye trauma or infection, or develop any eye reactions, immediately consult with your physician about continuing treatment with Rocklatan®.

Adverse reactions

The most common side effect for Rocklatan® in controlled clinical studies were red eyes (59%). Five percent of patients discontinued therapy due to red eyes. Other common side effects were pain upon instillation of eye drop (20%), small deposits on the outer surface of the eye (corneal verticillata) (15%), and broken blood vessels (11%). Eye itching, visual acuity reduced, excessive tearing, eye discomfort upon administration of eye drop, and blurred vision were reported in 5-8% of patients.

Be sure to contact your doctor if you have any questions.

Please click here for full prescribing information for Rocklatan®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATIONS AND USAGE

Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is a prescription medication for the treatment of high eye pressure/intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of Rocklatan® should not exceed once daily. Rocklatan® may be used together with other eye drops to lower high eye pressure/IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.